{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T20:05:02Z","timestamp":1774987502585,"version":"3.50.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81772707"],"award-info":[{"award-number":["81772707"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972732"],"award-info":[{"award-number":["81972732"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273965"],"award-info":[{"award-number":["82273965"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["7222006"],"award-info":[{"award-number":["7222006"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2023M732409"],"award-info":[{"award-number":["2023M732409"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2025T180744"],"award-info":[{"award-number":["2025T180744"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Metastatic clear cell renal cell carcinoma (ccRCC) remains lethal due to therapy resistance, and while dysregulated Wnt\/\u03b2-catenin signaling drives progression, its post-translational regulation is poorly understood. Through multi-omics analysis of TCGA\/GEO datasets, we identified MAGI3 as a key metastasis suppressor in ccRCC. Functional validation revealed that MAGI3 loss enhances invasion, migration and metastatic potential in vitro and in vivo. Mechanistically, MAGI3 binds \u03b2-catenin\u2019s C-terminus via PDZ domains, disrupting intramolecular N-terminus\u2013ARM domain interactions to expose phosphorylation sites, thereby enabling GSK-3\u03b2\u2013mediated \u03b2-catenin phosphorylation and ubiquitin-dependent degradation. Critically, low MAGI3 hyperactivates \u03b2-catenin and drives mTOR inhibitor resistance. Combining Everolimus with the Wnt inhibitor XAV-939 slashed viability and invasion in resistant cells. Clinically, patients whose tumors exhibited high MAGI3 and low \u03b2-catenin expression demonstrated significantly improved response to Everolimus therapy. In conclusion, MAGI3 is a critical gatekeeper of \u03b2-catenin destruction in ccRCC. Its loss defines a metastatic, therapy-resistant subtype targetable by dual mTOR\/Wnt blockade. Therefore, MAGI3 expression may stratify patients for personalized therapy.<\/jats:p>","DOI":"10.1038\/s41419-026-08563-x","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T15:39:49Z","timestamp":1774366789000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["MAGI3 deficiency unleashes \u03b2-catenin conformational change to drive metastatic progression and mTOR inhibitor resistance in ccRCC"],"prefix":"10.1038","volume":"17","author":[{"given":"Siyu","family":"Gu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1902-5251","authenticated-orcid":false,"given":"Haibo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengyan","family":"Fa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuan","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiong","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ran","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0197-630X","authenticated-orcid":false,"given":"Xiaomei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5921-1297","authenticated-orcid":false,"given":"Junqi","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"8563_CR1","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41581-020-00359-2","volume":"17","author":"E Jonasch","year":"2021","unstructured":"Jonasch E, Walker CL, Rathmell WK. Clear cell renal cell carcinoma ontogeny and mechanisms of lethality. Nat Rev Nephrol. 2021;17:245\u201361. https:\/\/doi.org\/10.1038\/s41581-020-00359-2.","journal-title":"Nat Rev Nephrol"},{"key":"8563_CR2","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.eururo.2018.08.036","volume":"75","author":"U Capitanio","year":"2019","unstructured":"Capitanio U, Bensalah K, Bex A, Boorjian SA, Bray F, Coleman J, et al. Epidemiology of renal cell carcinoma. Eur Urol. 2019;75:74\u201384. https:\/\/doi.org\/10.1016\/j.eururo.2018.08.036.","journal-title":"Eur Urol"},{"key":"8563_CR3","doi-asserted-by":"crossref","unstructured":"Ingels A, Campi R, Capitanio U, Amparore D, Bertolo R, Carbonara U, et al. Complementary roles of surgery and systemic treatment in clear cell renal cell carcinoma. Nat Rev Urol. 2022;19:391\u2013418.","DOI":"10.1038\/s41585-022-00592-3"},{"key":"8563_CR4","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.1002\/cncr.31341","volume":"124","author":"SP Psutka","year":"2018","unstructured":"Psutka SP, Master VA. Role of metastasis-directed treatment in kidney cancer. Cancer. 2018;124:3641\u201355. https:\/\/doi.org\/10.1002\/cncr.31341.","journal-title":"Cancer"},{"key":"8563_CR5","doi-asserted-by":"publisher","unstructured":"Christensen BR, Hajja YM, Koshkin V, Barata PC. Update on first-line combination treatment approaches in metastatic clear-cell renal cell carcinoma. Curr Treat Options Oncol. 2021;22.https:\/\/doi.org\/10.1007\/s11864-020-00814-z.","DOI":"10.1007\/s11864-020-00814-z"},{"key":"8563_CR6","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nm.3029","volume":"19","author":"S Vanharanta","year":"2013","unstructured":"Vanharanta S, Shu W, Brenet F, Hakimi AA, Massagu\u00e9 J. Epigenetic expansion of VHL-HIF signal output drives multi-organ metastasis in renal cancer. Nat Med. 2013;19:50\u20136. https:\/\/doi.org\/10.1038\/nm.3029.","journal-title":"Nat Med"},{"key":"8563_CR7","doi-asserted-by":"publisher","DOI":"10.1172\/JCI162480","volume":"132","author":"WG Kaelin Jr","year":"2022","unstructured":"Kaelin WG Jr. Von Hippel\u2014Lindau disease: insights into oxygen sensing, protein degradation, and cancer. J Clin Investig. 2022;132:e162480. https:\/\/doi.org\/10.1172\/JCI162480.","journal-title":"J Clin Investig"},{"key":"8563_CR8","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1038\/s41591-020-1093-z","volume":"26","author":"TK Choueiri","year":"2020","unstructured":"Choueiri TK, Kaelin WG. Targeting the HIF2\u2013VEGF axis in renal cell carcinoma. Nat Med. 2020;26:1519\u201330. https:\/\/doi.org\/10.1038\/s41591-020-1093-z.","journal-title":"Nat Med"},{"key":"8563_CR9","doi-asserted-by":"publisher","unstructured":"Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, et al. Renal cell carcinoma. Nat Rev Dis Primers. 2017;3. https:\/\/doi.org\/10.1038\/nrdp.2017.9.","DOI":"10.1038\/nrdp.2017.9"},{"key":"8563_CR10","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1007\/s12291-017-0713-y","volume":"33","author":"A Kumar","year":"2018","unstructured":"Kumar A, Kumari N, Gupta V, Prasad R. Renal cell carcinoma: molecular aspects. Indian J Clin Biochem. 2018;33:246\u201354. https:\/\/doi.org\/10.1007\/s12291-017-0713-y.","journal-title":"Indian J Clin Biochem"},{"key":"8563_CR11","doi-asserted-by":"publisher","unstructured":"Chen AH, Grana AK Belzutifan\u2019s role in the treatment landscape of clear cell renal cell carcinoma. Pharmacotherapy. 2025:356\u201366. https:\/\/doi.org\/10.1002\/phar.70023.","DOI":"10.1002\/phar.70023"},{"key":"8563_CR12","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nature19796","volume":"539","author":"W Chen","year":"2016","unstructured":"Chen W, Hill H, Christie A, Kim MS, Holloman E, Brugarolas J. Targeting renal cell carcinoma with a HIF-2 antagonist. Nature. 2016;539:112\u20137. https:\/\/doi.org\/10.1038\/nature19796.","journal-title":"Nature"},{"key":"8563_CR13","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/S1470-2045(13)70093-7","volume":"14","author":"RJ Motzer","year":"2013","unstructured":"Motzer RJ, Escudier B, Tomczak P, Hutson TE, Michaelson MD, Negrier S, et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol. 2013;14:552\u201362. https:\/\/doi.org\/10.1016\/S1470-2045(13)70093-7.","journal-title":"Lancet Oncol"},{"key":"8563_CR14","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1200\/JCO.2013.50.3961","volume":"32","author":"TE Hutson","year":"2014","unstructured":"Hutson TE, Escudier B, Esteban E, Bjarnason GA, Lim HY, Pittman KB, et al. Randomized phase iii trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2014;32:760\u20137. https:\/\/doi.org\/10.1200\/JCO.2013.50.3961.","journal-title":"J Clin Oncol"},{"key":"8563_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15586\/jkcvhl.2014.7","volume":"1","author":"C Morais","year":"2014","unstructured":"Morais C. Sunitinib resistance in renal cell carcinoma. J Kidney Cancer VHL. 2014;1:1\u201311.","journal-title":"J Kidney Cancer VHL"},{"key":"8563_CR16","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1093\/annonc\/mdu552","volume":"26","author":"R Elaidi","year":"2015","unstructured":"Elaidi R, Harbaoui A, Beuselinck B, Eymard JC, Bamias A, De Guillebon E, et al. Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma. Ann Oncol. 2015;26:378\u201385. https:\/\/doi.org\/10.1093\/annonc\/mdu552.","journal-title":"Ann Oncol"},{"key":"8563_CR17","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1038\/nrd2154","volume":"5","author":"N Barker","year":"2006","unstructured":"Barker N, Clevers H. Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov. 2006;5:997\u20131014. https:\/\/doi.org\/10.1038\/nrd2154.","journal-title":"Nat Rev Drug Discov"},{"key":"8563_CR18","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41585-018-0023-z","volume":"15","author":"SC Joosten","year":"2018","unstructured":"Joosten SC, Smits KM, Aarts MJ, Melotte V, Koch A, Tjan-Heijnen VC, et al. Epigenetics in renal cell cancer: mechanisms and clinical applications. Nat Rev Urol. 2018;15:430\u201351. https:\/\/doi.org\/10.1038\/s41585-018-0023-z.","journal-title":"Nat Rev Urol"},{"key":"8563_CR19","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3390\/cancers8060057","volume":"8","author":"Q Xu","year":"2016","unstructured":"Xu Q, Krause M, Samoylenko A, Vainio S. Wnt signaling in renal cell carcinoma. Cancers. 2016;8:57. https:\/\/doi.org\/10.3390\/cancers8060057.","journal-title":"Cancers"},{"key":"8563_CR20","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.jhep.2006.11.017","volume":"46","author":"J Behari","year":"2007","unstructured":"Behari J, Zeng G, Otruba W, Thompson M, Muller P, Micsenyi A, et al. R-Etodolac decreases beta-catenin levels along with survival and proliferation of hepatoma cells. J Hepatol. 2007;46:849\u201357.","journal-title":"J Hepatol"},{"key":"8563_CR21","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.canlet.2013.12.029","volume":"346","author":"V Gnemmi","year":"2014","unstructured":"Gnemmi V, Bouillez A, Gaudelot K, H\u00e9mon B, Ringot B, Pottier N, et al. MUC1 drives epithelial\u2013mesenchymal transition in renal carcinoma through Wnt\/\u03b2-catenin pathway and interaction with SNAIL promoter. Cancer Lett. 2014;346:225\u201336. https:\/\/doi.org\/10.1016\/j.canlet.2013.12.029.","journal-title":"Cancer Lett"},{"key":"8563_CR22","doi-asserted-by":"crossref","unstructured":"Kim YS, Kang YK, Kim JB, Han SA, Kim KI, Paik SR. \u03b2-Catenin expression and mutational analysis in renal cell carcinomas. Pathol Int. 2000;50:725\u201330.","DOI":"10.1046\/j.1440-1827.2000.01111.x"},{"key":"8563_CR23","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/his.13059","volume":"70","author":"G Kovacs","year":"2017","unstructured":"Kovacs G, Billfeldt NK, Farkas N, Dergez T, Javorhazy A, Banyai D, et al. Cytoplasmic expression of \u03b2-catenin is an independent predictor of progression of conventional renal cell carcinoma: a simple immunostaining score. Histopathology. 2017;70:273\u201380. https:\/\/doi.org\/10.1111\/his.13059.","journal-title":"Histopathology"},{"key":"8563_CR24","doi-asserted-by":"publisher","first-page":"3554","DOI":"10.1158\/0008-5472.CAN-20-3960","volume":"81","author":"H Rao","year":"2021","unstructured":"Rao H, Li X, Liu M, Liu J, Feng W, Tang H, et al. Multilevel regulation of \u03b2-catenin activity by SETD2 suppresses the transition from polycystic kidney disease to clear cell renal cell carcinoma. Cancer Res. 2021;81:3554\u201367. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-3960.","journal-title":"Cancer Res"},{"key":"8563_CR25","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.canlet.2019.03.043","volume":"453","author":"C Zhao","year":"2019","unstructured":"Zhao C, Tao T, Yang L, Qin Q, Wang Y, Liu H, et al. Loss of PDZK1 expression activates PI3K\/AKT signaling via PTEN phosphorylation in gastric cancer. Cancer Lett. 2019;453:107\u201321. https:\/\/doi.org\/10.1016\/j.canlet.2019.03.043.","journal-title":"Cancer Lett"},{"key":"8563_CR26","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1002\/ijc.31876","volume":"144","author":"Q Wang","year":"2019","unstructured":"Wang Q, Song R, Zhao C, Liu H, Yang Y, Gu S, et al. HPV16 E6 promotes cervical cancer cell migration and invasion by downregulation of NHERF1. Int J Cancer. 2019;144:1619\u201332. https:\/\/doi.org\/10.1002\/ijc.31876.","journal-title":"Int J Cancer"},{"key":"8563_CR27","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3892\/or.2017.5649","volume":"38","author":"Y Wang","year":"2017","unstructured":"Wang Y, Peng Z, Meng R, Tao T, Wang Q, Zhao C, et al. NHERF1 inhibits proliferation of triple-negative breast cancer cells by suppressing GPER signaling. Oncol Rep. 2017;38:221\u20138. https:\/\/doi.org\/10.3892\/or.2017.5649.","journal-title":"Oncol Rep"},{"key":"8563_CR28","doi-asserted-by":"publisher","unstructured":"Wang H, Yang W, Qin Q, Yang X, Yang Y, Liu H, et al. E3 ubiquitin ligase MAGI3 degrades c-Myc and acts as a predictor for chemotherapy response in colorectal cancer. Mol Cancer. 2022;21. https:\/\/doi.org\/10.1186\/s12943-022-01622-9.","DOI":"10.1186\/s12943-022-01622-9"},{"key":"8563_CR29","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.1038\/s41591-024-03086-4","volume":"30","author":"H Ebrahimi","year":"2024","unstructured":"Ebrahimi H, Dizman N, Meza L, Malhotra J, Li X, Dorff T, et al. Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. Nat Med. 2024;30:2576\u201385. https:\/\/doi.org\/10.1038\/s41591-024-03086-4.","journal-title":"Nat Med"},{"key":"8563_CR30","doi-asserted-by":"publisher","first-page":"a007898","DOI":"10.1101\/cshperspect.a007898","volume":"5","author":"JL Stamos","year":"2013","unstructured":"Stamos JL, Weis WI. The \u03b2-catenin destruction complex. Cold Spring Harb Perspect Biol. 2013;5:a007898. https:\/\/doi.org\/10.1101\/cshperspect.a007898.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"8563_CR31","doi-asserted-by":"publisher","first-page":"35851","DOI":"10.18632\/oncotarget.5323","volume":"6","author":"Q Ma","year":"2015","unstructured":"Ma Q, Yang Y, Feng D, Zheng S, Meng R, Fa P, et al. MAGI3 negatively regulates Wnt\/beta-catenin signaling and suppresses malignant phenotypes of glioma cells. Oncotarget. 2015;6:35851\u201365. https:\/\/doi.org\/10.18632\/oncotarget.5323.","journal-title":"Oncotarget"},{"key":"8563_CR32","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1002\/ijc.31662","volume":"144","author":"YL Park","year":"2019","unstructured":"Park YL, Kim HP, Cho YW, Min DW, Cheon SK, Lim YJ, et al. Activation of WNT\/\u03b2-catenin signaling results in resistance to a dual PI3K\/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations. Int J Cancer. 2019;144:389\u2013401. https:\/\/doi.org\/10.1002\/ijc.31662.","journal-title":"Int J Cancer"},{"key":"8563_CR33","doi-asserted-by":"publisher","first-page":"47902","DOI":"10.18632\/oncotarget.18146","volume":"8","author":"T Mashima","year":"2017","unstructured":"Mashima T, Taneda Y, Jang MK, Mizutani A, Muramatsu Y, Yoshida H, et al. mTOR signaling mediates resistance to tankyrase inhibitors in Wnt-driven colorectal cancer. Oncotarget. 2017;8:47902\u201315. https:\/\/doi.org\/10.18632\/oncotarget.18146.","journal-title":"Oncotarget"},{"key":"8563_CR34","doi-asserted-by":"publisher","first-page":"5420","DOI":"10.1096\/fj.201902895R","volume":"34","author":"Q Weng","year":"2020","unstructured":"Weng Q, Chen M, Yang W, Li J, Fan K, Xu M, et al. Integrated analyses identify miR-34c-3p\/MAGI3 axis for the Warburg metabolism in hepatocellular carcinoma. FASEB J. 2020;34:5420\u201334. https:\/\/doi.org\/10.1096\/fj.201902895R.","journal-title":"FASEB J"},{"key":"8563_CR35","first-page":"3906","volume":"13","author":"Q Zhang","year":"2021","unstructured":"Zhang Q, Ye F, Guo S, Xiao W, Zhang J, Qu Y, et al. Knockdown of lncRNA RMST protect against myocardial infarction through regulating miR-5692 and MAGI3 axis. Am J Transl Res. 2021;13:3906\u201316.","journal-title":"Am J Transl Res"},{"key":"8563_CR36","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s10735-021-10050-w","volume":"53","author":"M Xu","year":"2022","unstructured":"Xu M, Yu T. MiR-20b-5p contributes to the dysfunction of vascular smooth muscle cells by targeting MAGI3 in hypertension. J Mol Histol. 2022;53:187\u201397. https:\/\/doi.org\/10.1007\/s10735-021-10050-w.","journal-title":"J Mol Histol"},{"key":"8563_CR37","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1016\/j.ajpath.2018.07.026","volume":"188","author":"J Zhang","year":"2018","unstructured":"Zhang J, Ye Y, Chang DW, Lin S, Huang M, Tannir NM, et al. Global and targeted miRNA expression profiling in clear cell renal cell carcinoma tissues potentially links miR-155-5p and miR-210-3p to both tumorigenesis and recurrence. Am J Pathol. 2018;188:2487\u201396. https:\/\/doi.org\/10.1016\/j.ajpath.2018.07.026.","journal-title":"Am J Pathol"},{"key":"8563_CR38","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/kjm2.12320","volume":"37","author":"XG Wang","year":"2021","unstructured":"Wang XG, Zhu YW, Wang T, Chen B, Xing JC, Xiao W. MiR-483-5p downregulation contributed to cell proliferation, metastasis, and inflammation of clear cell renal cell carcinoma. Kaohsiung J Med Sci. 2021;37:192\u20139. https:\/\/doi.org\/10.1002\/kjm2.12320.","journal-title":"Kaohsiung J Med Sci"},{"key":"8563_CR39","doi-asserted-by":"publisher","unstructured":"Yang Z, Liu H, Song R, Lu W, Wang H, Gu S, et al. Reduced MAGI3 level by HPV18E6 contributes to Wnt\/b-catenin signaling activation and cervical cancer progression. FEBS Open Bio 2021:3051\u201362. https:\/\/doi.org\/10.1002\/2211-5463.13298.","DOI":"10.1002\/2211-5463.13298"},{"key":"8563_CR40","doi-asserted-by":"publisher","first-page":"28222","DOI":"10.1074\/jbc.M109.045039","volume":"284","author":"R Mo","year":"2009","unstructured":"Mo R, Chew T, Maher MT, Bellipanni G, Weinberg ES, Gottardi CJ. The terminal region of \u03b2-catenin promotes stability by shielding the armadillo repeats from the axin-scaffold destruction complex. J Biol Chem. 2009;284:28222\u201331. https:\/\/doi.org\/10.1074\/jbc.M109.045039.","journal-title":"J Biol Chem"},{"key":"8563_CR41","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41581-025-00983-w","volume":"21","author":"FH Burgers","year":"2025","unstructured":"Burgers FH, Van Der Mijn JCK, Seijkens TTP, Jedema I, Bex A, Haanen JBAG. Immunological features of clear-cell renal-cell carcinoma and resistance to immune checkpoint inhibitors. Nat Rev Nephrol. 2025;21:687\u2013701. https:\/\/doi.org\/10.1038\/s41581-025-00983-w.","journal-title":"Nat Rev Nephrol"},{"key":"8563_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers17101613","volume":"1613","author":"PA Nicoletta Bianchi","year":"2025","unstructured":"Nicoletta Bianchi PA, Aguiari G. Molecular mechanisms of drug resistance in clear cell renal cell carcinoma. Cancers. 2025;1613:1\u201328. https:\/\/doi.org\/10.3390\/cancers17101613.","journal-title":"Cancers"},{"key":"8563_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2022.110350","volume":"95","author":"PS Daisy","year":"2022","unstructured":"Daisy PS, Biswas I, Kuduvalli SS, Anitha TS. Crosstalk between PI3K\/AKT\/mTOR and WNT\/beta-Catenin signaling in GBM\u2014Could combination therapy checkmate the collusion? Cell Signal. 2022;95:110350. https:\/\/doi.org\/10.1016\/j.cellsig.2022.110350.","journal-title":"Cell Signal"},{"key":"8563_CR44","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1158\/1078-0432.CCR-14-3081","volume":"22","author":"O Arqu\u00e9s","year":"2016","unstructured":"Arqu\u00e9s O, Chicote I, Puig I, Tenbaum SP, Argil\u00e9s G, Dienstmann R, et al. Tankyrase inhibition blocks Wnt\/\u03b2-catenin pathway and reverts resistance to PI3K and AKT inhibitors in the treatment of colorectal cancer. Clin Cancer Res. 2016;22:644\u201356. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-3081.","journal-title":"Clin Cancer Res"},{"key":"8563_CR45","doi-asserted-by":"publisher","first-page":"4256","DOI":"10.1002\/cncr.25219","volume":"116","author":"RJ Motzer","year":"2010","unstructured":"Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma. Cancer. 2010;116:4256\u201365. https:\/\/doi.org\/10.1002\/cncr.25219.","journal-title":"Cancer"},{"key":"8563_CR46","doi-asserted-by":"publisher","first-page":"658","DOI":"10.4161\/cbt.10.7.13247","volume":"10","author":"G Banumathy","year":"2014","unstructured":"Banumathy G, Cairns P. Signaling pathways in renal cell carcinoma. Cancer Biol Ther. 2014;10:658\u201364. https:\/\/doi.org\/10.4161\/cbt.10.7.13247.","journal-title":"Cancer Biol Ther"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08563-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08563-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08563-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T19:26:08Z","timestamp":1774985168000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08563-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8563"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08563-x","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"assertion":[{"value":"22 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Written informed consent has been obtained from all subjects for the publication of their data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Human ccRCC tissue samples were collected with written informed consent and approved by the Ethics Committee of Capital Medical University (Approval No. 2015SY08), in accordance with the Declaration of Helsinki. Animal experiments were conducted following NIH guidelines for the care and use of laboratory animals and were approved by the Animal Ethics Committee of Capital Medical University (Protocol No. AEEI-2020-133).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"ETHICS APPROVAL AND CONSENT TO PARTICIPATE"}}],"article-number":"372"}}